Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc. (RCKT)
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2025
Reporting Period: Preliminary financial information for the quarter ended March 31, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification that preliminary financial information for the quarter ended March 31, 2025, has been announced via a press release (Exhibit 99.1), but the numerical data is not included in the body of this document.
Material Changes
No material changes or comparative financial data are detailed in the text of this filing. The document references a press release for the specific results but does not summarize the changes versus the prior comparable period.
Guidance, Outlook, and Risks
Management Commentary: The Company announced preliminary financial results for the quarter ended March 31, 2025.
Legal Disclaimer: The information furnished in this report and the attached press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 8, 2025) for the actual preliminary financial figures.
- Verify the specific revenue, net loss, and cash position for the quarter ended March 31, 2025, as these are absent from the 8-K text.
- Check for any updated guidance or operational milestones mentioned in the referenced press release.
- Confirm the status of the Company's cash runway and funding needs based on the preliminary data.